ID   LiPSC-PR1.0
AC   CVCL_RL67
SY   LiPSC-PR1
DR   GEO; GSM1854264
DR   Wikidata; Q54902577
RX   PubMed=26411904;
RX   PubMed=27283945;
CC   From: Lonza, Inc.; Basel; Switzerland.
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: In situ; Umbilical cord blood; UBERON=UBERON_0012168.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_RL68 ! LiPSC-PR2.0
OI   CVCL_RL69 ! LiPSC-PR3.0
SX   Female
AG   <1D
CA   Induced pluripotent stem cell
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 6
//
RX   PubMed=26411904; DOI=10.1016/j.stemcr.2015.08.015; PMCID=PMC4624993;
RA   Baghbaderani B.A., Tian X.-H., Neo B.H., Burkall A., DiMezzo T.,
RA   Sierra G., Zeng X.-M., Warren K., Kovarcik D.P., Fellner T., Rao M.S.;
RT   "cGMP-manufactured human induced pluripotent stem cells are available
RT   for pre-clinical and clinical applications.";
RL   Stem Cell Reports 5:647-659(2015).
//
RX   PubMed=27283945; DOI=10.1007/s12015-016-9662-8; PMCID=PMC4919381;
RA   Baghbaderani B.A., Syama A., Sivapatham R., Pei Y., Mukherjee O.,
RA   Fellner T., Zeng X.-M., Rao M.S.;
RT   "Detailed characterization of human induced pluripotent stem cells
RT   manufactured for therapeutic applications.";
RL   Stem Cell Rev. Rep. 12:394-420(2016).
//